Desimplification of Single Tablet Antiretroviral (ART) Regimens—A Practical Cost-Savings Strategy?
Hartmut Krentz PhD, Shayna Campbell BSc, John Gill MD
Journal of the International Association of Providers of AIDS Care · 2019
doi:10.1177/2325958218822304 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Introduction: The use of lifelong antiretroviral therapy (ART) results in increased costs of care; the ability to finance and control sustained costs of ART needs to be discussed. Approach: The Southern Alberta Clinic initiated a practical cost savings approach that switched select patients from a branded ART to a less expensive generic variation. Our approach surveyed physicians and patients on their acceptance of switching and then launched a program asking patients if they would switch to generic variations for cost control purposes. Results: Our early findings found >50% of patients approached agreed to switch. We found no evidence of increased risk of viral breakthrough, resistance, side effects, or displeasure with generic drugs. Measured cost savings in the first year were >$1.1 million with annual projected savings of between $4.3 million and $2.6 million (in 2017 Cdn$). Conclusion: Our approach can provide an option for controlling costs of HIV care without compromising quality.
Abstract licence: CC BY-NC
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.